Introduction {#S1}
============

Name giving, hepatocyte growth factor (HGF) was initially identified as a mitogenic factor for rat hepatocytes ([@B1], [@B2]). However, it then became evident that HGF elicits various biological activities in a number of different cell types. Independent studies before cloning of the HGF gene identified the same molecule as a potent inducer of epithelial cell motility (and thus termed as scatter factor) ([@B3]) and as a fibroblast-derived cytotoxic factor for some tumor cell lines ([@B4]). Furthermore, HGF was found to promote cell survival, tissue protection and regeneration but restrain fibrosis and inflammation ([@B5]). All these activities are commenced by binding of HGF to its cognate receptor Met, which was originally identified as a transforming oncogene ([@B6], [@B7]). HGF is primarily secreted by mesenchymal cells that are frequently positioned in the immediate vicinity of Met-expressing cells reflecting the limited capacity of HGF to diffuse *in vivo* ([@B8]). The indispensable roles of Met signaling by HGF for embryonic development and tissue regeneration have been demonstrated by targeted disruption of the HGF and Met genes. Both the conventional Met- or HGF-null mutations in mice result in a lethal phenotype *in utero* caused by the impaired development of placenta and liver ([@B9]--[@B11]). In addition, Met-expressing myogenic precursors fail to emigrate from the dermomyotome leading to the total absence of all muscle groups derived from these migratory progenitor cells ([@B10], [@B12]). The contribution of Met signaling to the long-range migration of cells during development is mediated by induction of a cell fate program known as epithelial--mesenchymal transition (EMT) that is fundamental not only during embryogenesis but also in tissue regeneration of the adult organism ([@B8], [@B13], [@B14]).

A corresponding aberrant activation of the EMT program by Met signaling during tumorgenesis results in invasive growth and metastasis of tumor cells ([@B8], [@B13], [@B14]). The oncogenic role and potential interventions of the Met signaling pathway for tumor therapy have long been a major focus of research, which is comprehensively documented in a number of excellent reviews ([@B5], [@B15]--[@B18]). However, a growing body of evidence suggests an additionally important role of Met signaling in control of immune cell functions and thus in regulation of immunity. Here, we will discuss the current understanding of Met signaling and function in dendritic cells (DCs) with particular emphasis on the motogenic activities of Met for Langerhans cells (LCs).

Structural and Functional Features of HGF and MET {#S2}
=================================================

Hepatocyte Growth Factor {#S2-1}
------------------------

Biologically active HGF is a disulfide-linked heterodimeric molecule composed of a 69 kDa α-chain and a 34 kDa β-chain that is derived from an inactive single-chain precursor (pro-HGF; Figure [1](#F1){ref-type="fig"}) ([@B5]). HGF and the structurally similar cytokine macrophage-stimulating protein (MST1, also known as HGF-like or MSP) comprise the unique group of plasminogen-like cytokines ([@B19]). Unlike other cytokines and growth factors, they share structural homologies with coagulation factors, including prothrombin, coagulation factor XII, plasminogen and plasminogen activators (urokinase type, u-Pa and tissue type, t-Pa), and HGF activator protein (HGFA). They have in common the presence of a serine proteinase homology (SPH) domain and at least one kringle domain. HGF and MST1 have lost the proteinase activity due to loss of catalytic residues in the SPH domain but retained the requirement for proteolytic cleavage to become mature proteins ([@B20], [@B21]). The α-chain of HGF with four kringle domains confers high-affinity binding to the Met receptor and its dimerization, while subsequent binding of the β-chain is required for the activation of Met signaling ([@B22]).

![The domain structure of hepatocyte growth factor (HGF) and Met. HGF and Met are both synthesized as inert single-chain precursors and are cleaved to generate mature disulfide-linked α--β heterodimers that have signaling competence. The α-chain of HGF contains an N-terminal hairpin loop and four kringle domains, and the β-chain harbors a catalytically inactive serine proteinase homology domain. Important for ligand binding the α-chain of Met and the amino-terminal end of the β-chain form a so-called Sema domain found in semaphorin axon-guidance proteins and plexins (cell adhesion and semaphorin receptors). The remainder of the extracellular part of the β-chain contains a PSI domain (present in plexins, semaphorins, and integrins) and four IPT domains (immunoglobulin-like fold shared by plexins and transcription factors). IPT3 and IPT4 serve as the high-affinity docking site for HGF. The cytoplasmic region comprises the tyrosine kinase domain, a juxtamembrane regulatory region, and a multiprotein-docking site at the carboxy terminus essential for downstream signaling.](fimmu-09-00517-g001){#F1}

A complex process is regulating the availability of bioactive HGF. Both pro-HGF and cleaved HGF bind with high affinity to heparan sulfate proteoglycans that limits the diffusion and leads to accumulation within the extracellular matrix (ECM) ([@B23]). Pro-HGF can be cleaved by many serine proteinases present in serum or cell membrane including u-Pa, t-Pa, plasma kallikrein, factor XII, HGFA, and others ([@B5]). Among them, HGFA is one of the most efficient in processing pro-HGF. Again, HGFA like other serine proteinases of this family is synthesized as an inactive single-chain precursor (pro-HGFA) that needs proteolytic cleavage, e.g., by the central coagulation factor thrombin to become an active proteinase ([@B24]). The contribution of the coagulation cascade to the activation of HGF strongly points toward the significant role of HGF in tissue injury ([@B25]). In addition, the activity of HGFA is regulated by specific inhibitors of the Kunitz-type family of membrane-bound serine protease inhibitors, namely, HGFA inhibitor 1 (HAI-1) and HAI-2 ([@B26]). HGFA activity is suppressed by binding to HAI-1 on the cell surface. The HGFA/HAI-1 complexes on the cell surface can be released by metalloproteinase-mediated shedding of the HAI-1 ectodomain ([@B5]). Interestingly, DCs also express HAI-1 and thus may themselves be capable of regulating the availability of bioactive HGF in injured tissue and inflammation ([@B27]). Notably, pro-inflammatory mediators, including IL-1β and prostaglandin E2, are potent inducers of HGF expression and cleavage of HAI-1 ([@B5]). The regulatory mechanisms that control HGF activity thus refer to the mutual link of inflammation with tissue damage and regeneration.

Met {#S2-2}
---

All biological functions of HGF are exerted by binding to its unique receptor Met. Like its ligand, Met is synthesized as an immature single-chain precursor that is cleaved by intracellular endoproteinases to form the mature membrane-bound disulfide-linked α-β heterodimer (Figure [1](#F1){ref-type="fig"}). Met shares similar structural features with the receptor for MST1 (MST1R; also known as Ron/CD136 or as STK in mice) ([@B28], [@B29]). The mature form of Met comprises the extracellular 50 kDa α-chain and the transmembrane-passing 145 kDa β-chain. The so-called Sema domain constituted by the α-chain and the amino-terminal end of the β-chain is required for HGF binding and activation of Met signaling ([@B30]). Upon HGF binding, Met undergoes dimerization and autophosphorylation of two critical tyrosine residues in the activation loop of the kinase domain, leading to enhanced catalytic activity ([@B14]). Further phosphorylation of tyrosine residues within the C-terminal docking site controls recruitment of various signaling and adaptor proteins that in turn can activate downstream signaling pathways, such as ERK, AKT, and RAC1 pathways ([@B8], [@B14], [@B31]).

Met interacts with other cell surface receptor that can modulate Met signaling in ligand-dependent and -independent manner. Remarkably, this includes a number of surface receptors involved in regulation of cellular motility and migration, such as integrin α6β4 ([@B32]), plexin-B1 ([@B33]), CD44 ([@B34], [@B35]), Mif receptor ([@B36]), and E-cadherin ([@B37]). Met and plexins share the highly homologous Sema domain that allows physical interactions between them ([@B38]). Consequently, semaphorin binding to plexins can lead to Met transactivation independent from HGF binding ([@B14]). The expression of different members of the plexin family on DCs and their contribution to the regulation of DC migration has already been described ([@B39]--[@B41]), suggesting that this may involve interaction with Met signaling.

The Immunoregulatory Function of HGF/MET Signaling {#S3}
==================================================

Beyond the well-recognized role of Met signaling in epithelial cells and tumor development, early reports already provided evidence for a role in hematopoietic cells ([@B42], [@B43]), and accumulating data from recent years clearly demonstrated important functions in hematopoiesis and immunity.

Constitutive Met expression is limited to hematopoietic progenitor cells and their antigen-presenting progenies, including B cells, monocytes/macrophages, and DCs ([@B29], [@B44]). However, exposure to pro-inflammatory cytokines leads to induction and/or upregulation of Met expression in various cell types, again pointing toward the regulatory link of tissue injury to the inflammatory response. Indeed, recent findings suggest conditionally inducible expression of Met in other immune cells including neutrophils ([@B45]) and a specific subset of CD8+ T cells ([@B46]). Interestingly, in neutrophils, the Met expression was found to be required for chemoattraction in response to HGF and transmigration across an endothelial barrier ([@B45]). This provides further evidence that Met signaling can exert motogenic functions in immune cells. Met signaling was reported to play a role in regulating B cell homing to lymph nodes (LNs) ([@B47]) and was identified as a potent inducer of directional migration in monocytes ([@B48], [@B49]). Likewise, Met expression was found to regulate splenic DC function ([@B50], [@B51]) and was further shown to be expressed on bone marrow (BM)-derived DCs, dermal DCs, and LCs ([@B52], [@B53]).

For the Met ligand HGF, it has been shown that it---frequently in synergy with other growth factors---can support erythropoiesis, thrombopoiesis, and myelopoiesis and development of Met-expressing thymocytes ([@B5], [@B43]). Fibroblast-like stromal cells in lymphoid tissues including spleen ([@B54]), LNs ([@B47]), thymus ([@B55]), and BM ([@B56]) constitutively produce HGF that can be modulated by activated T cells ([@B54]). HGF might thus play additional roles within lymphoid organs on Met-expressing cells, such as regulation of cell survival ([@B36]) and cytokine production ([@B50], [@B51], [@B57]--[@B59]), thereby influencing immune responses (Figure [2](#F2){ref-type="fig"}). Moreover, also hematopoietic cells including platelets, mast cells, neutrophils, and macrophages can produce HGF.

![Hepatocyte growth factor (HGF)/Met signaling in Langerhans cells (LCs)/dendritic cells (DCs). Schematic representation of two major avenues of Met signaling on DCs in peripheral and lymphoid tissues. Met signaling induces LC and dermal DC emigration from skin in an epithelial--mesenchymal transition (EMT)-like process, including matrix metalloproteinase (MMP) activation to facilitate arrival to draining lymph nodes and antigen presentation to naive T cells. HGF induces tolerogenic phenotypes by IL-10 and IL-27 secretion and upregulated expression of, e.g., glucocorticoid-induced leucine zipper (GILZ) and programmed-death ligand 1 (PD-L1) in DCs, which eventually results in enhanced numbers of regulatory T cells (T~regs~).](fimmu-09-00517-g002){#F2}

In response to infection or tissue injury the production of HGF is further stimulated by pro-inflammatory cytokines, including IL-1α, IL-1β, TNF-α, and IL-6 ([@B60], [@B61]). By contrast, anti-inflammatory factors, such as glucocorticoids ([@B62]), 1,25-dihydroxyvitamin D3 ([@B63]), and TGF-β ([@B64]), inhibit HGF production. This points toward a potential pro-inflammatory role of HGF. In line with this concept, stimulation of monocytes with HGF induced upregulation of pro-inflammatory factors, including IL-4, IL-1β, GM-CSF, and MIP-1β ([@B48]). This notion was further fueled by studies, which showed that HGF stimulated the antigen presentation capacity of adult human blood monocytes ([@B65]) and that in the murine experimental autoimmune encephalomyelitis (EAE) model Met signaling promoted the development of M1 macrophages fostering inflammation ([@B66]).

In addition to its pro-inflammatory role, it has been proposed that HGF exerts anti-inflammatory activities ([@B5]). Indeed, HGF was found to grant protective effects in various animal models of inflammatory diseases, including collagen-induced arthritis ([@B58]), chronic airway inflammation ([@B50]), inflammatory bowel disease ([@B67], [@B68]), and even in EAE in contrast to the previously cited study ([@B51], [@B69]) by regulating various functions of immune cells, including cytokine production, migration, and adhesion. A number of these studies provided strong evidence that HGF-mediated immunomodulatory effects were imparted *via* direct impact on DC function (Figure [2](#F2){ref-type="fig"}). HGF was shown to impair DC activation resulting in an obstructed antigen-presenting capacity ([@B50], [@B70]), and that HGF inhibited immunogenic DC function by stimulating IL-10 secretion ([@B59]), which leads to suppression of the DC function in an autocrine manner ([@B71]). In the EAE model, HGF was shown to confer DCs with suppressive competence resulting in induction of regulatory T cells (T~regs~) ([@B51], [@B59], [@B69]). Noteworthy, HGF treatment of DCs was found to increase expression of programmed-death ligand 1 and IL-27, which are potent factors to mediate DC-driven generation of T~regs~ ([@B69]). In addition, DCs exhibited increased glucocorticoid-induced leucine zipper (GILZ) expression upon HGF stimulation. Notably, previous studies revealed GILZ expression to be a shared feature of tolerogenic DCs induced by IL-10, TGF-β, and glucocorticoids ([@B72], [@B73]) (which in turn can regulate HGF expression; see above). These results strongly indicate that HGF exerts immunoregulatory activities directly through Met-dependent regulation of DC function. However, an immunoregularory function of HGF/Met signaling in skin immunity has been scarcely explored.

MET Signaling in Skin Injury and the Impact on LC Migration {#S4}
===========================================================

The skin represents one of the largest organs of the human body that also establishes a direct interface between the organism and its environment. As such, the skin acts as a physical and an immunological barrier to protect the body from dangerous substances and pathogens ([@B74]). However, the skin can also be easily wounded and then becomes a main entry route for foreign pathogens. Again, it is highly conceivable that the mechanisms of tissue regeneration, including HGF/Met signaling, are interrelated with immune regulatory mechanisms. Surprisingly, there are only a few studies revealing a role of the HGF/Met signaling pathway in skin injury and inflammation.

A study employing a mouse model with conditionally disrupted Met gene in epidermal keratinocytes revealed an indispensable role for the HGF--Met pathway in skin wound healing ([@B75]). Particularly, Met-deficient epidermal keratinocytes failed to restore skin wound re-epithelialization, while other growth factors and bioactive molecules were functional. Further studies provided additional mechanistic insights and thus corroborated the role of Met signaling in keratinocytes for wound healing ([@B76]--[@B78]). Interestingly, keratinocytes are a source of HGF upon skin injury in humans ([@B79]).

A previous study identified dermal fibroblasts as a major source of HGF in skin upon infection or stimulation with pro-inflammatory cytokines ([@B80]) indicating a role for HGF/Met signaling also in dermal tissue homeostasis. Indeed, in the tight-skin mouse, a genetic model of human systemic sclerosis HGF was shown to ameliorate dermal sclerosis ([@B81]). The tight-skin mouse model exhibits fibrosis and thickening of subcutaneous dermal tissue, which was diminished upon HGF treatment. Exogenous HGF was found to suppress expression of IL-4 and TGF-β mRNA ([@B81]), which has been suggested to impact on fibrogenesis and in the hypodermal thickness of tight-skin mice ([@B81], [@B82]). In particular, HGF was found to inhibit the production of IL-4 in CD4+ T cells stimulated by allogeneic DCs, and it is tempting to speculate that this was due to Met-mediated activity of HGF on DCs.

Clear evidence for the role of Met signaling in skin DCs came again from studies using a conditional Met-knockout mouse model ([@B83]) in which DC-dependent contact hypersensitivity (CHS) reactions were addressed ([@B53]). Skin DC populations including LCs were found to express Met, and HGF stimulation effectively activated Met signaling and induced LC emigration from skin (Figure [2](#F2){ref-type="fig"}) ([@B52], [@B53]). By contrast, skin-resident DCs in Met-deficient mice upon activation failed to emigrate from skin toward the draining LNs although DCs displayed an activated phenotype ([@B53]). Consequently, Met-deficiency resulted in strongly impaired CHS reactions in response to contact allergens, which could be also achieved by pharmacological inhibition of Met signaling in wild-type control mice. Emigration of resident LCs from the skin upon stimulation requires a multitude of tissue remodeling capacities that allows detachment from surrounding tissue, adherence to and migration through ECM, and crossing tissue boundaries. Met signaling was found essential in migration of BM-derived DCs through ECM that requires matrix metalloproteinase (MMP) activities for matrix degradation. Indeed, proteolytic activity of both MMP-2 and MMP-9 was found regulated by Met in BM-derived DCs ([@B53]), in line with previous studies that revealed a critical role of MMP-2 and MMP-9 in LC migration (Figure [2](#F2){ref-type="fig"}) ([@B84]--[@B86]). In summary, these findings established Met signaling as a key mechanism of LC detachment from the epidermal tissue and emigration from the skin upon activation.

MET-Driven EMT in LCs as a Regulator of Skin Immunity {#S5}
=====================================================

The regulation of LC mobilization and migration by HGF/Met signaling upon inflammatory activation results in a series of phenotypic conversions comprising, e.g., detachment from surrounding tissue and activation of MMPs resulting in interstitial migration and crossing of tissue boundaries. Collectively, all these phenotypic alterations have a striking analogy to a Met signal-driven mechanism identified during embryonic development, wound healing, and invasive growth of tumors known as EMT ([@B8], [@B13], [@B14], [@B87]--[@B89]). The genetic program underlying this process leads to the transient conversion of immobile epithelial cells into a migratory mesenchymal phenotype. Thus, we propose the concept that a genetic program similar to EMT is accomplished by Met signaling in LCs ([@B29], [@B53]). Similar to Met-driven EMT of epithelial cells, LCs need to disrupt their physical contact to neighboring cells mediated by adherens and tight junctions. A major molecular hallmark of EMT is the loss of E-cadherin expression. EMT is further characterized by the downregulation of various other factors involved in formation of adherens and tight junction structures, including zonula occludens (ZO) proteins, cytokeratins, occludins, claudins, and EpCAM leading to the disassembly of cell-to-cell contacts ([@B88]--[@B90]). Cells simultaneously acquire a mesenchymal phenotype, including the expression of N-cadherin, vimentin, integrins, and MMPs and reorganization of their cytoskeleton, which collectively enable cell migration. Again, it has been well recognized that the Met-driven stimulation of proteolytic MMP activity advances tumor cell dissociation and scattering ([@B87]--[@B89]). The EMT program is controlled by an intricate network of transcriptional regulators including basic helix--loop--helix factors (e.g., Twist1) and zinc finger and E-box binding proteins (ZEB) 1 and 2 \[reviewed in Ref. ([@B89]--[@B91])\].

Langerhans cells in skin express a broad range of epithelial-like adhesive molecules that permit the functional integration into the keratinocyte layer. This includes tight junction proteins, such as claudin-1 and ZO-1 ([@B92], [@B93]), which have been shown to maintain tight junction integrity during antigen uptake ([@B93]). Furthermore, human LCs derived in a well-established *in vitro* model showed in addition expression of occludin, ZO-3, JAM1, and cytokeratins (CK8 and CK18) ([@B94]), and it is highly conceivable that this is also true *in vivo*. LCs also express adherens junction proteins that mediate homophilic binding to other cells, including E-cadherin, EpCAM/TROP1, and TROP2 ([@B95]--[@B97]), and the specific impacts of E-cadherin and EpCAM on LC motility, migration, and function have been well recognized ([@B98]--[@B100]). Remarkably, the maturation of activated LCs toward a migratory phenotype revealed downregulation of E-cadherin and EpCAM, accompanied by upregulated expression of N-cadherin and the EMT regulators ZEB1 and ZEB2 ([@B98], [@B101], [@B102]). These findings, together with the regulation of MMPs in DCs described earlier, support the notion that a Met-driven EMT program is accomplished after LCs are activated ([@B29]).

Concluding Remarks {#S6}
==================

In summary, Met signaling in skin resident DCs including LCs appears to be a critical determinant for maintaining normal immune function and as an important constituent that interlaces tissue regenerative functions with the appropriate immune responses that must be accomplished after tissue injury, infection, or inflammation. Other studies suggest a protective role of HGF/Met signaling against autoimmunity by directing DCs toward a tolerogenic phenotype. This and a number of further activities of HGF/Met signaling on other immune cells suggest the HGF/Met pathway as a potential target for treatment of inflammatory and autoimmune disorders, including skin diseases and transplantation ([@B103], [@B104]). Due to the critical role of Met signaling for tumor invasion and metastasis, drug targeting of the Met receptor and/or pathways is highly considered as a potential means for therapy of a number of epithelial cancers. Consequently, attempts to block Met-induced migration of tumor cells may lead to altered immune functions in cancer patients and thus possibly to increased susceptibility to infection and/or development of autoimmune disorders. Conversely, approaches to promote immune tolerance *via* HGF/Met in immune cells could concurrently stimulate potential tumor cells toward invasive growth. The knowledge of the HGF/Met signaling mechanisms in DCs is still in its infancy and must be extended to (i) develop save Met-based therapies in the future and (ii) corroborate the concept that a Met-driven execution of an EMT program in DCs is indeed a generic mechanism.
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